MedTrace Logo

Determinants of Bone and Muscle Quality and Strength in Obesity With and Without Diabetes

NCT04093856 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2021-09-01

No results posted yet for this study

Summary

Background: Osteoporotic fractures are a major public health issue. They cause substantial disability, loss of autonomy, morbidity and excess mortality. Diabetes is also associated with increased risk for falls and fractures through a direct impact of elevated blood glucose on the skeleton and on muscles.

Research project overview: The investigators propose a cross-sectional study that will involve 2 research centers in the province of Quebec. The investigators will recruit 20 obese participants, without diabetes, who have not undergone bariatric surgery, for one-time measurements to be compared with baseline measurements (pre-surgery) from participants in the bariatric obese diabetic groups with type II diabetes mellitus from the ongoing study BODI study (NCT03455868). Bone Mineral Density as well as muscle quality, strength and function will be evaluated at a single study visit.

Relevance: This data will permit the evaluation of the bone-muscle unit in patients with obesity with and without diabetes, and assess whether the presence and duration of diabetes impacts further on clinical and functional musculoskeletal outcomes (falls, fractures and mobility and strength) in this population. AGEs, if associated with muscle and bone deterioration, might become an easily accessible biomarker of musculoskeletal health in the clinical setting.

Conditions

  • Diabetes Mellitus
  • Diabetes Mellitus, Type 2
  • Obesity
  • Body Weight
  • Bone Diseases, Metabolic
  • Fractures, Bone
  • Osteoporotic Fractures
  • Osteoporosis
  • Quality of Life
  • Fall
  • Musculoskeletal Diseases

Sponsors & Collaborators

  • CHU de Quebec-Universite Laval

    collaborator OTHER

  • Suzanne Morin

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-14
Primary Completion
2021-06-14
Completion
2021-06-14

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04093856 on ClinicalTrials.gov